Ziprasidone: Difference between revisions
ClaireLewis (talk | contribs) (Created page with "==Administration== *Type: Atypical antipsychotic *Dosage Forms: *Routes of Administration: PO, IM *Common Trade Names: Geodon ==Adult Dosing== *Mania/psychosis: 40 to 80 mg P...") |
|||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: Atypical antipsychotic | *Type: Atypical [[antipsychotic]] | ||
*Dosage Forms: | *Dosage Forms: | ||
*Routes of Administration: PO, IM | *Routes of Administration: PO, IM | ||
Revision as of 19:27, 13 November 2016
Administration
- Type: Atypical antipsychotic
- Dosage Forms:
- Routes of Administration: PO, IM
- Common Trade Names: Geodon
Adult Dosing
- Mania/psychosis: 40 to 80 mg PO BID
- Acute agitation: 10-20mg IM q2-4h, 40mg max daily
Pediatric Dosing
- Age 10-17: slowly titrate up to target dose 20-80mg BID
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: no adjustment
- Hepatic dosing: no adjustment
Contraindications
- Allergy to class/drug
- QT prolongation, concomittant administration of other QT prolonging medications
- Decompensated heart failure, recent MI
Adverse Reactions
Serious
- Prolonged QT, torsades de pointes, syncope
- Neuroleptic malignant syndrome, tardive dyskinesia, seizure
- Bone marrow depression
- Dysphagia
- Hyperglycemia, diabetes
- Priapism
Common
- Extrapyramidal disease, dystonia, tremor, akathisia
- Dizziness, asthenia, somnolence, anxiety
- Nausea/vomiting, diarrhea, constipation
- Weight gain
- Rash
- Visual changes
- URI
Pharmacology
- Half-life: 2-7h
- Metabolism: Hepatic: CYP3A4, and CYP1A2
- Excretion: Mostly fecal
Mechanism of Action
- D2 and 5HT2 antagonist. Also strong alpha-1 blocker, antihistamine-1.